Hematologic Malignancies Program

Experts Present Findings at Annual ASH Conference

UMGCC Hematologic Malignancies Program member participation in the 2008 American Society of Hematology Annual Meeting, December 6-9, 2008, San Francisco

Dr. Yin Wu, second-year Hematology/Oncology fellow mentored by Dr. Ashraf Badros, presented “Outcome of African-American multiple myeloma patients after autologous stem cell transplantation: A single-center experience.”

Dr. Yingqiu Xie, postdoctoral fellow in Dr. Maria Baer’s laboratory, presented “PKC412 directly inhibits the serine/threonine protein kinase pim-1 in cell lines and acute myeloid leukemia cells as a novel mechanism of inhibition of multidrug resistance.”

Dr. Feyruz Rassool presented “Inhibiting alternative non-homologous enjoining (NHEJ) pathways: Therapeutic targets in chronic myeloid leukemia.”

Dr. Ashraf Badros, Dr. Maria Baer and Dr. Ivana Gojo were co-investigators and co-authors of presentations of clinical trials results. Dr. Badros: “Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: Early clinical experience,” “Phase II trial of combination of bortezomib and rituximab in Relapsed and/or refractory Waldenstrom macroglobulinemia,” and “A phase 1 trial of SNS-032, a potent and specific CDK 2, 7 and 9 inhibitor, in chronic lymphocytic leukemia and multiple myeloma.” Dr. Baer: “Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes,” and “Phase II trial of low dose, subcutaneous decitabine in myelofibrosis.” Dr. Gojo: “Minimizing therapy for patients with acute promyelocytic leukemia: Efficacy of single cycle of arsenic-based consolidation therapy,” and “Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.”

Dr. Ashraf Badros gave a presentation entitled “B-cell neoplasms“in a Satellite Symposium entitled “The Hematology Circle: Optimizing Epigenetic Therapy to Improve Outcomes” and Dr. Maria Baer gave a presentation entitled “Have new agents for MDS made a difference?“ in a Satellite Symposium entitled “Treating AML/MDS in the Elderly: New Solutions for a Long-standing Problem.”

Dr. Ann Zimrin gave a presentation entitled “Measuring Outcomes” in the Hematology/Oncology Training Program Directors’ Workshop.

Dr. Aaron Rapoport and Dr. Douglas Ross served as abstract reviewers and chaired scientific sessions.

For more information about the Hematologic Malignancies Program at UMGCC, please call 410-328-2567.

This page was last updated on: January 9, 2009.